Owners of French drug delivery device manufacturer Nemera are exploring a potential sale of their majority stake, valued at roughly €3 billion ($3.5 billion), following a surge in demand for devices linked to GLP-1 weight-loss drugs and insulin therapies.
The sale process, still in early stages, is expected to begin in the coming months, according to people familiar with the matter. Last year, private equity firms Astorg Partners and Montagu Private Equity brought in LGT Capital Partners as a minority shareholder, a move that preceded the current strategic review.
Nemera specializes in the production of auto-injectors, pens, inhalers, eye droppers, and pumps, with manufacturing operations spanning the US, France, Germany, Poland, and Brazil. The company’s portfolio has positioned it to benefit from the rapid expansion of the pharmaceutical delivery device sector, driven by rising adoption of GLP-1 medications and insulin treatments.
The potential sale reflects broader industry dynamics, as demand for specialized drug delivery systems accelerates alongside the growth of weight-loss and diabetes therapies. No formal decision has been made, and discussions remain preliminary.
